Provided/Edited by Avulux
Avulux added into FDA-funded pediatrics product portfolio to address migraines
March 26, 2025
Avulux, the provider of a clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, announced that the Consortium for Technology & Innovation in Pediatrics (CTIP) has added Avulux into its product portfolio to address migraines.
What is CTIP?
Established in 2011 at Chicago’s Lurie Children’s Hospital and Children’s Hospital Los Angeles, CTIP connects clinicians, engineers, regulators, patients and businesses while providing portfolio companies with networking, financial support and guidance on intellectual property, prototyping, testing and clinical trials across its 25-organization network spanning eight states.
Challenge: Addressing Pediatric Migraines
Pediatric eye care and migraine present unique challenges as children struggle to describe symptoms, complicating diagnosis between visual disturbances and migraine.
Other Articles to Explore
According to the National Institute of Health (NIH), about 1 in 10 children experience migraine, and, in fact, up to 18% of patients in the pediatric emergency room are found to be migraine related. Migraine can also significantly impair school performance and quality of life in children.
Avulux says its product is the only lens that has been clinically proven for people living with migraine and light sensitivity.
In a 2020 double blind, randomized, placebo-controlled study conducted by an independent clinical research organization, the Avulux lens achieved both clinical and statistical significance when compared to a clear placebo lens.
Addressing Migraines in Children Under-Served Need
“Migraine in children is often under-diagnosed and under-treated, despite the profound impact on development, education and overall well-being,” said Juan Espinoza, MD, Director and Principal Investigator of CTIP. “At CTIP, we are committed to supporting innovations like Avulux that offer non-invasive and effective solutions to improve the lives of pediatric patients.”
Added Charles Posternack, MD, CEO of Avulux: “Visual symptoms such as light sensitivity are often the most disabling component of migraine for children, thus optometrists are well positioned to make a real difference in their lives.
Migraine prevalence in children also increases with age, with up to 24% of teenagers experiencing at least one migraine attack. Avulux looks forward to joining CTIP and contributing to advancing pediatric health.”
Click HERE to read how one doctor is using Avulux in her practice address migraines.
